Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07257484 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 9 wordsv6
  2. Recruitment openedv5 Show 5 more changesShow less
    • Primary completion pushed from Oct 6, 2027 to Dec 3, 2027
    • Study completion pushed from Dec 30, 2027 to Feb 25, 2028
    • Start date changed from estimate of Apr 6, 2026 to Jun 8, 2026
    • Eligibility criteria revised
    • Site details revised
  3. Start date: Jan 5, 2026 to Apr 6, 2026v4 Show 4 more changesShow less
    • Primary completion date: Jul 6, 2027 to Oct 6, 2027
    • Study completion date: Sep 30, 2027 to Dec 30, 2027
    • Eligibility criteria shortened, about 8 words
    • Secondary endpoints: 17 to 19
  4. Eligibility criteria expanded, about 50 wordsv3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.
Trial Details
NCT Number NCT07257484
Lead Sponsor Weill Medical College of Cornell University
Collaborators: National Center for Advancing Translational Sciences (NCATS)
Conditions
(from sponsor)		 Obesity (Disorder), Breast Cancer
Related terms Breast Neoplasms, Obesity
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov